Stock Price Targets and Analyst Ratings

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
AAOI Applied Optoelectronics	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mike Genovese Subscribe to MarketBeat All Access for the recommendation accuracy rating	$22.11 +39.3%	$36.00 ➝ $36.00	Buy ➝ Buy
AAPL Apple	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Ives Subscribe to MarketBeat All Access for the recommendation accuracy rating	$213.49 +1.8%	$325.00 ➝ $325.00	Outperform ➝ Outperform
ABNB Airbnb	Target Raised by	Tigress Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ivan Feinseth Subscribe to MarketBeat All Access for the recommendation accuracy rating	$122.86 +2.9%	$195.00 ➝ $200.00	Buy ➝ Buy
ACIU AC Immune	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.29 -0.4%	$16.00 ➝ $16.00	Buy ➝ Buy
ACN Accenture	Target Lowered by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Ramnani Subscribe to MarketBeat All Access for the recommendation accuracy rating	$318.28 +0.4%	$429.00 ➝ $396.00	Overweight ➝ Overweight
AEO American Eagle Outfitters	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Nardone Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.06 +0.7%	$18.00 ➝ $13.00	Neutral ➝ Neutral
AFCG AFC Gamma	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Hurwit Subscribe to MarketBeat All Access for the recommendation accuracy rating	$6.62 -2.1%	$10.00 ➝ $7.00	Buy ➝ Hold
AKBA Akebia Therapeutics	Target Raised by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Allison Bratzel Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.26 +33.7%	$4.00 ➝ $6.00	Overweight ➝ Overweight
AKBA Akebia Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ed Arce Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.26 +33.7%	$7.50 ➝ $7.50	Buy ➝ Buy
ALAB Astera Labs	Initiated by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Srini Pajjuri Subscribe to MarketBeat All Access for the recommendation accuracy rating	$72.18 +10.5%	$82.00	Outperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
ALLO Allogene Therapeutics	Upgraded by	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.94 +2.6%	$5.00	Market Perform ➝ Outperform
ALLO Allogene Therapeutics	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	John Newman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.94 +2.6%	$14.00 ➝ $14.00	Buy ➝ Buy
ALLO Allogene Therapeutics	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.94 +2.6%	$10.00 ➝ $10.00	Outperform ➝ Outperform
ALT Altimmune	Reiterated by	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hsieh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.92 +13.8%		Market Perform
AMD Advanced Micro Devices	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Rakesh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$100.97 +2.9%	$140.00 ➝ $120.00	Outperform ➝ Outperform
AMTX Aemetis	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Amit Dayal Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.68 +5.7%	$28.00 ➝ $28.00	Buy ➝ Buy
ANIP ANI Pharmaceuticals	Initiated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the recommendation accuracy rating	$62.49 +1.7%	$80.00	Buy
APD Air Products and Chemicals	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Spector Subscribe to MarketBeat All Access for the recommendation accuracy rating	$291.82 -0.4%	$395.00 ➝ $370.00	Buy ➝ Buy
ARCB ArcBest	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jordan Alliger Subscribe to MarketBeat All Access for the recommendation accuracy rating	$73.35 +0.4%	$126.00 ➝ $108.00	Neutral ➝ Neutral
ASTL Algoma Steel Group	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$9.40 +4.4%	C$21.00 ➝ C$15.25	Buy
ATAT Atour Lifestyle	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ronald Leung Subscribe to MarketBeat All Access for the recommendation accuracy rating	$31.25 +5.5%	$35.30 ➝ $36.80	Buy ➝ Buy
ATYR Atyr PHARMA	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the recommendation accuracy rating	$3.97 -0.5%	$35.00 ➝ $35.00	Buy ➝ Buy
ATZ Aritzia	Target Lowered by	CIBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$52.40 +0.3%	C$1.80 ➝ C$1.20	Underperform
AVAH Aveanna Healthcare	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A.J. Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.19 +1.0%	$3.20 ➝ $4.50	Sell ➝ Sell
AVNT Avient	Initiated by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		$40.33 +2.1%	$43.00	Neutral
AVNT Avient	Upgraded by	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Panjabi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$40.33 +2.1%		Hold
AXP American Express	Upgraded by	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. George Subscribe to MarketBeat All Access for the recommendation accuracy rating	$266.04 +3.7%		Strong Sell ➝ Hold
AXP American Express	Upgraded by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	David George Subscribe to MarketBeat All Access for the recommendation accuracy rating	$266.04 +3.7%	$265.00 ➝ $265.00	Underperform ➝ Neutral
BBW Build-A-Bear Workshop	Reiterated by	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Baker Subscribe to MarketBeat All Access for the recommendation accuracy rating	$36.42 +3.0%	$50.00 ➝ $50.00	Buy ➝ Buy
BDT Bird Construction	Target Lowered by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$21.51 +5.3%	C$32.00 ➝ C$30.00	Sector Perform
BDT Bird Construction	Target Lowered by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$21.51 +5.3%	C$36.00 ➝ C$35.00	Buy
BDT Bird Construction	Target Lowered by	CIBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$21.51 +5.3%	C$36.00 ➝ C$31.00
BDT Bird Construction	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$21.51 +5.3%	C$38.00 ➝ C$37.00	Buy
BLDP Ballard Power Systems	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ameet Thakkar Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.32 +3.1%	$1.30 ➝ $1.20	Underperform ➝ Underperform
BLDP Ballard Power Systems	Target Lowered by	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Craig Irwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.32 +3.1%	$1.75 ➝ $1.25	Neutral ➝ Neutral
BLDP Ballard Power Systems	Target Lowered by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.32 +3.1%	$2.50 ➝ $2.00	Market Perform
BLDP Ballard Power Systems	Target Lowered by	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.32 +3.1%	$1.90 ➝ $1.40	Hold
BLDP Ballard Power Systems	Target Lowered by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.32 +3.1%	$2.60 ➝ $2.00	Sector Perform
BLNK Blink Charging	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Pierce Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.95 +6.0%		Hold ➝ Hold
BLNK Blink Charging	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sameer Joshi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.95 +6.0%	$8.00 ➝ $8.00	Buy ➝ Buy
DOGE officially begins retirement transformation (Ad) Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history. Here's everything you need to do BEFORE Elon has the chance to make his biggest move yet.
BLNK Blink Charging	Target Lowered by	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mickey Legg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.95 +6.0%	$5.00 ➝ $2.00	Buy ➝ Buy
BLNK Blink Charging	Reiterated by	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Craig Irwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.95 +6.0%	$4.00 ➝ $3.00	Buy ➝ Buy
BXP Boston Properties	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Anthony Powell Subscribe to MarketBeat All Access for the recommendation accuracy rating	$65.55 +2.5%	$89.00 ➝ $79.00	Equal Weight ➝ Equal Weight
CAAP Corporación América Airports	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Guilherme Mendes Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.43 +2.8%	$22.50	Overweight
CABGY Carlsberg A/S	Upgraded by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$26.65 +3.1%		Sector Perform ➝ Outperform
CADL Candel Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vernon Bernardino Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.75 +10.2%	$19.00 ➝ $19.00	Buy ➝ Buy
CCI Crown Castle	Upgraded by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ric Prentiss Subscribe to MarketBeat All Access for the recommendation accuracy rating	$103.20 +8.5%	$128.00 ➝ $122.00	Outperform ➝ Strong-Buy
CCI Crown Castle	Upgraded by	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brandon Nispel Subscribe to MarketBeat All Access for the recommendation accuracy rating	$103.20 +8.5%	$120.00	Sector Weight ➝ Overweight
CCI Crown Castle	Upgraded by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Batya Levi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$103.20 +8.5%	$118.00 ➝ $118.00	Neutral ➝ Buy
CCI Crown Castle	Target Lowered by	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Maher Yaghi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$103.20 +8.5%	$102.00 ➝ $99.00	Sector Perform ➝ Sector Perform
CCI Crown Castle	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Rollins Subscribe to MarketBeat All Access for the recommendation accuracy rating	$103.20 +8.5%	$106.00 ➝ $108.00	Buy ➝ Buy
CCL Carnival Co. &	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Steven Wieczynski Subscribe to MarketBeat All Access for the recommendation accuracy rating	$19.93 +4.2%	$34.00 ➝ $30.00	Buy ➝ Buy
CCLD CareCloud	Reiterated by	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Baldry Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.47 -8.1%	$3.50 ➝ $1.50	Neutral ➝ Neutral
CCRN Cross Country Healthcare	Reiterated by	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Steinke Subscribe to MarketBeat All Access for the recommendation accuracy rating	$15.58 -1.1%	$18.61 ➝ $18.61	Market Perform ➝ Market Perform
$Calfrac Well Services Ltd. stock logo$ CFW Calfrac Well Services	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$3.69 +5.1%	C$5.00 ➝ C$4.50	Sector Perform
CHE Chemed	Target Raised by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the recommendation accuracy rating	$598.15 +1.4%	$633.00 ➝ $667.00	Outperform ➝ Outperform
CHKP Check Point Software Technologies	Upgraded by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Nowinski Subscribe to MarketBeat All Access for the recommendation accuracy rating	$224.84 +4.6%	$200.00 ➝ $280.00	Equal Weight ➝ Overweight
CHTR Charter Communications	Initiated by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Rollins Subscribe to MarketBeat All Access for the recommendation accuracy rating	$351.50 +1.8%	$425.00	Buy
CL Colgate-Palmolive	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrea Teixeira Subscribe to MarketBeat All Access for the recommendation accuracy rating	$89.80 -0.8%	$97.00 ➝ $99.00	Overweight ➝ Overweight
CMG Chipotle Mexican Grill	Upgraded by	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Alton Stump Subscribe to MarketBeat All Access for the recommendation accuracy rating	$50.12 +2.8%	$58.00 ➝ $65.00	Hold ➝ Buy
CNTY Century Casinos	Target Lowered by	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chad Beynon Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.90 -0.5%	$6.00 ➝ $5.00	Outperform ➝ Outperform
CNTY Century Casinos	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Steven Wieczynski Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.90 -0.5%	$5.00 ➝ $4.00	Buy ➝ Buy
COMP Compass	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Bernie McTernan Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.74 +0.1%	$12.00 ➝ $12.00	Buy ➝ Buy
COR Cencora	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	$258.09 +0.8%	$251.00 ➝ $274.00	Equal Weight ➝ Equal Weight
CPRT Copart	Downgraded by	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Staszak Subscribe to MarketBeat All Access for the recommendation accuracy rating	$52.65 +0.7%		Buy ➝ Hold
CTRE CareTrust REIT	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$28.35 +2.3%	$26.00 ➝ $26.00	Underperform ➝ Underperform
CURV Torrid	Reiterated by	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dana Telsey Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.02 +4.7%	$5.00 ➝ $5.00	Market Perform ➝ Market Perform
CVNA Carvana	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael McGovern Subscribe to MarketBeat All Access for the recommendation accuracy rating	$181.37 +8.8%	$270.00 ➝ $220.00	Buy ➝ Buy
DG Dollar General	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robert Ohmes Subscribe to MarketBeat All Access for the recommendation accuracy rating	$79.15 -1.0%	$95.00 ➝ $90.00	Buy ➝ Buy
DG Dollar General	Target Raised by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Peter Keith Subscribe to MarketBeat All Access for the recommendation accuracy rating	$79.15 -1.0%	$79.00 ➝ $81.00	Neutral ➝ Neutral
DHR Danaher	Upgraded by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the recommendation accuracy rating	$211.09 +3.4%	$260.00	Hold ➝ Buy
DINO HF Sinclair	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Connor Lynagh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$32.36 +4.3%	$51.00 ➝ $50.00	Overweight ➝ Overweight
DINO HF Sinclair	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Theresa Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$32.36 +4.3%	$37.00 ➝ $35.00	Equal Weight ➝ Equal Weight
DK Delek US	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Connor Lynagh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$15.66 +7.1%	$19.00 ➝ $18.00	Underweight ➝ Underweight
DKS DICK'S Sporting Goods	Reiterated by	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Feldman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$194.74 +4.4%	$250.00 ➝ $250.00	Outperform ➝ Outperform
DLTH Duluth	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jonathan Komp Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.28 -9.9%	$3.50 ➝ $2.75	Neutral ➝ Neutral
DOCU DocuSign	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Turrin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%	$70.00 ➝ $73.00	Underweight ➝ Underweight
DOCU DocuSign	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Ives Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%	$100.00 ➝ $100.00	Neutral ➝ Neutral
DOCU DocuSign	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Karl Keirstead Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%	$100.00 ➝ $90.00	Neutral ➝ Neutral
DOCU DocuSign	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tyler Radke Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%	$113.00 ➝ $115.00	Buy ➝ Buy
DOCU DocuSign	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rishi Jaluria Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%	$90.00 ➝ $90.00	Sector Perform ➝ Sector Perform
DOCU DocuSign	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Scott Berg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%		Hold ➝ Hold
DOCU DocuSign	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brad Sills Subscribe to MarketBeat All Access for the recommendation accuracy rating	$85.76 +14.8%	$112.00 ➝ $98.00	Neutral ➝ Neutral
DOL Dollarama	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$149.98 +1.5%	C$154.00 ➝ C$160.00
EFX Equifax	Downgraded by	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Grobler Subscribe to MarketBeat All Access for the recommendation accuracy rating	$235.96 -0.3%	$265.00	Outperform ➝ Neutral
EMP.A Empire	Upgraded by	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$43.48 +2.5%	C$47.00 ➝ C$49.00	Sector Perform ➝ Outperform
EMX EMX Royalty	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Heiko Ihle Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.85	$7.00 ➝ $5.00	Buy ➝ Buy
EPAC Enerpac Tool Group	Initiated by	CJS Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Moore Subscribe to MarketBeat All Access for the recommendation accuracy rating	$44.06 +3.6%	$53.00	Outperform
EPD Enterprise Products Partners	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Theresa Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$33.54 +1.7%	$35.00 ➝ $37.00	Overweight ➝ Overweight
ETNB 89bio	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrea Newkirk Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.47 +3.5%	$11.00	Neutral
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad) If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry. You MUST act before March 17th.
EVCM EverCommerce	Target Lowered by	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Schwartz Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.36 +4.6%	$13.00 ➝ $12.00	Outperform ➝ Outperform
EVCM EverCommerce	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Macwilliams Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.36 +4.6%	$12.00 ➝ $9.00	Equal Weight ➝ Equal Weight
EVCM EverCommerce	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gabriela Borges Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.36 +4.6%	$9.00 ➝ $8.00	Sell ➝ Sell
EVCM EverCommerce	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Hedberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.36 +4.6%	$14.00 ➝ $11.00	Outperform ➝ Outperform
EVCM EverCommerce	Target Lowered by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Samad Samana Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.36 +4.6%	$12.00 ➝ $10.00	Hold ➝ Hold
EVEX EVE	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andres Sheppard Subscribe to MarketBeat All Access for the recommendation accuracy rating	$3.19 -2.9%	$5.00 ➝ $5.00	Overweight ➝ Overweight
FLTR Flutter Entertainment	Reiterated by	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		£181.55 +0.8%	£247	Buy
FLWS 1-800-FLOWERS.COM	Reiterated by	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Linda Bolton Weiser Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.84 -3.2%	$7.50 ➝ $7.50	Neutral ➝ Neutral
FMBH First Mid Bancshares	Target Lowered by	Hovde Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$35.45 +1.3%	$48.00 ➝ $43.00	Outperform
FMX Fomento Económico Mexicano	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rodrigo Alcantara Subscribe to MarketBeat All Access for the recommendation accuracy rating	$99.04 +1.4%	$94.00 ➝ $107.00	Neutral ➝ Neutral
FN Fabrinet	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mike Genovese Subscribe to MarketBeat All Access for the recommendation accuracy rating	$220.85 -1.3%	$285.00 ➝ $285.00	Buy ➝ Buy
FORA VerticalScope	Target Raised by	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$9.92 -1.8%	C$17.00 ➝ C$18.00	Buy
FORA VerticalScope	Target Raised by	Cormark Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$9.92 -1.8%	C$14.00 ➝ C$19.00
FORA VerticalScope	Target Raised by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$9.92 -1.8%	C$13.00 ➝ C$14.50	Outperform
FORA VerticalScope	Target Raised by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$9.92 -1.8%	C$13.00 ➝ C$15.00	Outperform
FRU Freehold Royalties	Target Raised by	Desjardins Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$12.61 +2.5%	C$16.50 ➝ C$17.00	Buy
FUN Cedar Fair	Initiated by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brandt Montour Subscribe to MarketBeat All Access for the recommendation accuracy rating	$37.88 +8.0%	$41.00	Overweight
FUTU Futu	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Katherine Lei Subscribe to MarketBeat All Access for the recommendation accuracy rating	$118.47 +10.2%	$160.00 ➝ $170.00	Overweight ➝ Overweight
FVR FrontView REIT	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kilichowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	$14.52 +0.2%	$20.00 ➝ $19.00	Overweight ➝ Overweight
GBIO Generation Bio	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		$0.48 -6.3%	$5.00	Outperform
GBIO Generation Bio	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.48 -6.3%	$8.00 ➝ $8.00	Buy ➝ Buy
GDOT Green Dot	Upgraded by	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Sutton Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.73 +16.3%	$14.00	Hold ➝ Buy
GIII G-III Apparel Group	Target Lowered by	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dana Telsey Subscribe to MarketBeat All Access for the recommendation accuracy rating	$26.67 +2.2%	$38.00 ➝ $30.00	Market Perform ➝ Market Perform
GIS General Mills	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Thomas Palmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	$59.53 -0.5%	$60.00 ➝ $58.00	Neutral ➝ Neutral
GOSS Gossamer Bio	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.45 +11.5%	$4.00 ➝ $4.00	Outperform ➝ Outperform
GRPN Groupon	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eric Sheridan Subscribe to MarketBeat All Access for the recommendation accuracy rating	$14.85 -0.1%	$8.00 ➝ $9.00	Sell ➝ Sell
GSY goeasy	Upgraded by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Ricard Subscribe to MarketBeat All Access for the recommendation accuracy rating	C$148.86 +5.6%	C$207.00 ➝ C$200.00	Market Perform ➝ Outperform
HAIN The Hain Celestial Group	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ken Goldman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$3.82 -12.0%	$6.00 ➝ $5.00	Neutral ➝ Neutral
HBR Harbour Energy	Target Lowered by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 189.60 +2.0%	GBX 360 ➝ GBX 260	Buy
HEINY Heineken	Upgraded by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating	$42.86 +1.8%		Sector Perform ➝ Outperform
HGBL Heritage Global	Target Lowered by	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mark Argento Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.36 +12.9%	$5.00 ➝ $4.00	Buy ➝ Buy
HQY HealthEquity	Reiterated by	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Alexander Paris Subscribe to MarketBeat All Access for the recommendation accuracy rating	$97.41 +3.7%	$112.00 ➝ $112.00	Outperform ➝ Outperform
HSBA HSBC	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 870 +2.0%	GBX 1,035	Buy
HSY Hershey	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Carey Subscribe to MarketBeat All Access for the recommendation accuracy rating	$170.32 -0.9%	$125.00 ➝ $132.00	Underweight ➝ Underweight
IDOX IDOX	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 58.40 +2.8%	GBX 90	Buy
INAB IN8bio	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Swayampakula Ramakanth Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.23 -0.4%	$8.00 ➝ $6.00	Buy ➝ Buy
INSE Inspired Entertainment	Reiterated by	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Scharf Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.37 +4.2%	$14.00	Market Outperform ➝ Market Outperform
INSE Inspired Entertainment	Target Set by	New Street Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Bain Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.37 +4.2%	$21.00
INSE Inspired Entertainment	Target Set by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Barry Jonas Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.37 +4.2%	$19.00
IPA ImmunoPrecise Antibodies	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Swayampakula Ramakanth Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.38 -5.0%	$7.00 ➝ $7.00	Buy ➝ Buy
KALV KalVista Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	$12.60 +2.9%	$20.00 ➝ $20.00	Buy ➝ Buy
KLTR Kaltura	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Koontz Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.85 -1.1%	$3.00 ➝ $3.00	Buy ➝ Buy
KNOS Kainos Group	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 720 +4.7%	GBX 1,000	Speculative Buy
KOO Kooth	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 140 -1.8%	GBX 580	Buy
LCTX Lineage Cell Therapeutics	Target Lowered by	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mayank Mamtani Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.52	$4.00 ➝ $3.00	Buy ➝ Buy
LDI loanDepot	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Douglas Harter Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.39 +1.1%	$2.00 ➝ $1.35	Neutral ➝ Neutral
LRN Stride	Reiterated by	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Alexander Paris Subscribe to MarketBeat All Access for the recommendation accuracy rating	$120.93 +2.1%	$140.00 ➝ $140.00	Outperform ➝ Outperform
LYRA Lyra Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Caufield Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.17 -1.7%	$2.00 ➝ $2.00	Neutral ➝ Neutral
MANH Manhattan Associates	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	George Kurosawa Subscribe to MarketBeat All Access for the recommendation accuracy rating	$172.50 +5.5%	$244.00 ➝ $184.00	Neutral ➝ Neutral
MANH Manhattan Associates	Target Lowered by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Quinton Gabrielli Subscribe to MarketBeat All Access for the recommendation accuracy rating	$172.50 +5.5%	$268.00 ➝ $200.00	Overweight ➝ Overweight
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad) If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry. You MUST act before March 17th.
MC Moelis & Company	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	James Yaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$59.61 +1.8%	$86.00 ➝ $75.00	Neutral ➝ Neutral
MCK McKesson	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	$650.96 +1.1%	$641.00 ➝ $691.00	Equal Weight ➝ Equal Weight
MCRB Seres Therapeutics	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.69 +8.1%	$1.00 ➝ $0.75	Sell ➝ Sell
MHC.UN Flagship Communities Real Estate Investment Trust	Target Raised by	Desjardins Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$23.74 +4.4%	C$19.50 ➝ C$20.50	Buy
MHC.UN Flagship Communities Real Estate Investment Trust	Target Raised by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$23.74 +4.4%	C$19.00 ➝ C$20.00	Strong-Buy
MHC.UN Flagship Communities Real Estate Investment Trust	Target Raised by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$23.74 +4.4%	C$20.00 ➝ C$21.00	Outperform
MNOV MediciNova	Reiterated by	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.55 +5.4%	$9.00 ➝ $9.00	Buy ➝ Buy
MNTK Montauk Renewables	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Manav Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.07 -16.9%	$6.25 ➝ $3.00	Neutral ➝ Neutral
MNTK Montauk Renewables	Target Lowered by	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Pfingst Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.07 -16.9%	$4.00 ➝ $3.00	Neutral ➝ Neutral
MPC Marathon Petroleum	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Theresa Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$141.23 +3.1%	$159.00 ➝ $161.00	Overweight ➝ Overweight
MPLX Mplx	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Theresa Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$53.43 +2.0%	$52.00 ➝ $55.00	Overweight ➝ Overweight
MYRG MYR Group	Upgraded by	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sangita Jain Subscribe to MarketBeat All Access for the recommendation accuracy rating	$117.21 +5.0%	$136.00	Sector Weight ➝ Overweight
NABL N-able	Target Raised by	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Vandrick Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.61 -3.0%	$8.75 ➝ $9.00	Sector Perform ➝ Sector Perform
NABL N-able	Reiterated by	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		$7.61 -3.0%		Outperform
NABL N-able	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mike Cikos Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.61 -3.0%	$10.00 ➝ $10.00	Buy ➝ Buy
NCMI National CineMedia	Upgraded by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Alicia Reese Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.95 +4.2%	$7.50 ➝ $7.50	Neutral ➝ Outperform
NCMI National CineMedia	Reiterated by	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Sholl Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.95 +4.2%	$7.00 ➝ $7.00	Outperform ➝ Outperform
NET Netcall	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 114.50 +3.6%	GBX 130	Buy
NET Cloudflare	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Borges Subscribe to MarketBeat All Access for the recommendation accuracy rating	$115.83 +1.9%	$183.00 ➝ $161.00	Buy ➝ Buy
NFI NFI Group	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	C$13.42 +20.8%	C$14.00 ➝ C$13.00
NKTR Nektar Therapeutics	Upgraded by	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.90 +10.0%	$6.00	Market Perform ➝ Outperform
NOTE FiscalNote	Target Lowered by	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Baldry Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.91 -5.7%	$3.00 ➝ $2.00	Buy ➝ Buy
NOTE FiscalNote	Target Lowered by	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Zach Cummings Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.91 -5.7%	$1.75 ➝ $1.50	Buy ➝ Buy
NRXP NRx Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vernon Bernardino Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.35 +13.5%	$19.00 ➝ $19.00	Buy ➝ Buy
NUVL Nuvalent	Upgraded by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Dai Subscribe to MarketBeat All Access for the recommendation accuracy rating	$77.01 +3.4%	$100.00 ➝ $100.00	Neutral ➝ Buy
NVDA NVIDIA	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Rakesh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$121.67 +5.3%	$175.00 ➝ $168.00	Outperform ➝ Outperform
NVMI Nova	Target Lowered by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Prisco Subscribe to MarketBeat All Access for the recommendation accuracy rating	$219.13 +1.8%	$315.00 ➝ $300.00	Overweight ➝ Overweight
NYXH Nyxoah	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.51 +4.6%	$16.00 ➝ $15.00	Buy ➝ Buy
OSB OSB Group	Reiterated by	Shore Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 455.60 +3.9%		Buy
PATH UiPath	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keith Bachman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.84 +8.8%	$16.00 ➝ $11.50	Market Perform ➝ Market Perform
PBF PBF Energy	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Connor Lynagh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$20.70 +5.2%	$31.00 ➝ $28.00	Equal Weight ➝ Equal Weight
PD PagerDuty	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Hedberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.41 +17.9%	$24.00 ➝ $22.00	Outperform ➝ Outperform
PD PagerDuty	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joel Fishbein Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.41 +17.9%	$30.00 ➝ $26.00	Buy ➝ Buy
PD PagerDuty	Target Lowered by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kingsley Crane Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.41 +17.9%	$24.00 ➝ $23.00	Buy ➝ Buy
PD PagerDuty	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kash Rangan Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.41 +17.9%	$21.00 ➝ $18.00	Neutral ➝ Neutral
PEN Penumbra	Initiated by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the recommendation accuracy rating	$273.51 +4.9%	$320.00	Buy
PGR Progressive	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Meredith Subscribe to MarketBeat All Access for the recommendation accuracy rating	$283.87 +1.6%	$275.00 ➝ $285.00	Neutral ➝ Neutral
PHAR Pharming Group	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.77 +0.3%	$37.00 ➝ $37.00	Buy ➝ Buy
PHAR Pharming Group	Target Raised by	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Carrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.77 +0.3%	$30.00 ➝ $39.00	Outperform ➝ Outperform
PIPR Piper Sandler Companies	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Yaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$254.06 +0.8%	$321.00 ➝ $286.00	Neutral ➝ Neutral
PIPR Piper Sandler Companies	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Yaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$254.06 +0.8%	$321.00 ➝ $286.00	Neutral ➝ Neutral
PM Philip Morris International	Upgraded by	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Coleman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$151.95 +1.0%		Hold ➝ Buy
POW Power Co. of Canada	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$48.92 +1.5%	C$49.00 ➝ C$52.00
PRKS United Parks & Resorts	Initiated by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brandt Montour Subscribe to MarketBeat All Access for the recommendation accuracy rating	$47.71 +4.5%	$50.00	Equal Weight
PRQR ProQR Therapeutics	Reiterated by	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.69 -2.9%	$4.00 ➝ $4.00	Buy ➝ Buy
PRQR ProQR Therapeutics	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.69 -2.9%	$10.00 ➝ $12.00	Buy ➝ Buy
PSX Phillips 66	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Theresa Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$126.84 +3.5%	$115.00 ➝ $135.00	Equal Weight ➝ Equal Weight
PTCT PTC Therapeutics	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eric Joseph Subscribe to MarketBeat All Access for the recommendation accuracy rating	$54.50 +3.3%	$72.00 ➝ $78.00	Overweight ➝ Overweight
PTON Peloton Interactive	Upgraded by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Susan Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.05 +16.1%	$10.00	Hold ➝ Buy
PWP Perella Weinberg Partners	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	James Yaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$19.48 -0.8%	$23.00 ➝ $20.00	Sell ➝ Sell
Trump doesn’t give a damn (Ad) Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom… Go here now to find out the names of these 10 stocks.
QBTS D-Wave Quantum	Target Raised by	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Suji Desilva Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.19 +47.4%	$7.00 ➝ $10.00	Buy ➝ Buy
QBTS D-Wave Quantum	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Williams Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.19 +47.4%	$8.00 ➝ $8.00	Buy ➝ Buy
QBTS D-Wave Quantum	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Quinn Bolton Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.19 +47.4%	$8.50 ➝ $8.50	Buy ➝ Buy
QBTS D-Wave Quantum	Target Raised by	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Craig Ellis Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.19 +47.4%	$11.00 ➝ $12.00	Buy ➝ Buy
RBRK Rubrik	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keith Bachman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$70.54 +27.6%	$72.00 ➝ $77.00	Outperform ➝ Outperform
RBRK Rubrik	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Ruykhaver Subscribe to MarketBeat All Access for the recommendation accuracy rating	$70.54 +27.6%	$85.00 ➝ $85.00	Overweight ➝ Overweight
RBRK Rubrik	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Nowinski Subscribe to MarketBeat All Access for the recommendation accuracy rating	$70.54 +27.6%	$76.00 ➝ $80.00	Overweight ➝ Overweight
RBRK Rubrik	Target Raised by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Ives Subscribe to MarketBeat All Access for the recommendation accuracy rating	$70.54 +27.6%	$75.00 ➝ $80.00	Outperform ➝ Outperform
RBRK Rubrik	Target Raised by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	James Fish Subscribe to MarketBeat All Access for the recommendation accuracy rating	$70.54 +27.6%	$83.00 ➝ $87.00	Overweight ➝ Overweight
RBRK Rubrik	Target Lowered by	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eric Heath Subscribe to MarketBeat All Access for the recommendation accuracy rating	$70.54 +27.6%	$87.00 ➝ $82.00	Overweight ➝ Overweight
RC Ready Capital	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Douglas Harter Subscribe to MarketBeat All Access for the recommendation accuracy rating	$5.02 -0.9%	$7.00 ➝ $5.00	Neutral ➝ Neutral
RELX Relx	Upgraded by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Julien Roch Subscribe to MarketBeat All Access for the recommendation accuracy rating	$48.99 +2.5%		Equal Weight ➝ Overweight
RGLS Regulus Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Raghuram Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.48 +7.2%	$10.00 ➝ $10.00	Buy ➝ Buy
RGNX REGENXBIO	Reiterated by	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniil Gataulin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$6.72 +2.6%	$52.00 ➝ $52.00	Buy ➝ Buy
RGNX REGENXBIO	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Judah Frommer Subscribe to MarketBeat All Access for the recommendation accuracy rating	$6.72 +2.6%	$22.00 ➝ $24.00	Overweight ➝ Overweight
RNAC Cartesian Therapeutics	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mitchell Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	$15.80 -4.9%	$45.00 ➝ $40.00	Buy ➝ Buy
RVLV Revolve Group	Upgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Randal Konik Subscribe to MarketBeat All Access for the recommendation accuracy rating	$22.27 +4.7%	$30.00	Hold ➝ Buy
SANA Sana Biotechnology	Initiated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Roger Song Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.93 +10.6%	$7.00	Buy
SARO StandardAero	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kristine Liwag Subscribe to MarketBeat All Access for the recommendation accuracy rating	$28.60 -1.3%	$33.00 ➝ $32.00	Equal Weight ➝ Equal Weight
SKLZ Skillz	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		$4.40 -14.0%	$15.00	Outperform
SKWD Skyward Specialty Insurance Group	Upgraded by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the recommendation accuracy rating	$49.78 +5.1%	$53.00 ➝ $63.00	Equal Weight ➝ Overweight
SMTC Semtech	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Arcuri Subscribe to MarketBeat All Access for the recommendation accuracy rating	$39.60 +21.1%	$65.00 ➝ $60.00	Buy ➝ Buy
SMTC Semtech	Target Lowered by	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Acree Subscribe to MarketBeat All Access for the recommendation accuracy rating	$39.60 +21.1%	$82.00 ➝ $68.00	Buy ➝ Buy
SMTC Semtech	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Quinn Bolton Subscribe to MarketBeat All Access for the recommendation accuracy rating	$39.60 +21.1%	$54.00 ➝ $54.00	Buy ➝ Buy
SMTC Semtech	Target Lowered by	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		$39.60 +21.1%	$70.00 ➝ $55.00	Buy
SMTC Semtech	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tore Svanberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$39.60 +21.1%	$60.00 ➝ $54.00	Buy ➝ Buy
SOL Emeren Group	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Amit Dayal Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.19 -19.4%	$7.00 ➝ $7.00	Buy ➝ Buy
SPIR Spire Global	Target Lowered by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Austin Moeller Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.61 -3.0%	$15.00 ➝ $14.50	Buy ➝ Buy
STRO Sutro Biopharma	Downgraded by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.81 -35.2%	$11.00 ➝ $1.00	Buy ➝ Underperform
STRO Sutro Biopharma	Downgraded by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.81 -35.2%	$8.00 ➝ $2.00	Outperform ➝ Neutral
STRO Sutro Biopharma	Downgraded by	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.81 -35.2%		Outperform ➝ Market Perform
SUN Sunoco	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Theresa Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$57.78 +0.6%	$59.00 ➝ $62.00	Overweight ➝ Overweight
TARA Protara Therapeutics	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Li Watsek Subscribe to MarketBeat All Access for the recommendation accuracy rating	$4.31 +7.2%		Overweight
TBCH Turtle Beach	Target Raised by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Pachter Subscribe to MarketBeat All Access for the recommendation accuracy rating	$13.56 -5.1%	$20.00 ➝ $21.00	Outperform ➝ Outperform
TCRX TScan Therapeutics	Reiterated by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Maxwell Skor Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.74 -2.8%	$10.00	Overweight
TER Teradyne	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Moore Subscribe to MarketBeat All Access for the recommendation accuracy rating	$86.74 +1.7%	$112.00 ➝ $81.00	Underweight ➝ Underweight
TLYS Tilly's	Target Lowered by	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Koranda Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.41 -8.7%	$5.00 ➝ $2.50	Neutral ➝ Neutral
TMUS T-Mobile US	Downgraded by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Rollins Subscribe to MarketBeat All Access for the recommendation accuracy rating	$255.98 -1.2%	$268.00	Buy ➝ Neutral
TRML Tourmaline Bio	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Yi Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.80 +10.3%	$49.00 ➝ $50.00	Buy ➝ Buy
TRML Tourmaline Bio	Target Raised by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chico Subscribe to MarketBeat All Access for the recommendation accuracy rating	$18.80 +10.3%	$42.00 ➝ $43.00	Outperform ➝ Outperform
TSLA Tesla	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Colin Langan Subscribe to MarketBeat All Access for the recommendation accuracy rating	$249.98 +3.9%	$135.00 ➝ $130.00	Underweight ➝ Underweight
TSVT 2seventy bio	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	$4.95	$6.00 ➝ $5.00	Equal Weight ➝ Equal Weight
TTAN ServiceTitan	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Berg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$93.00 +12.9%	$125.00 ➝ $125.00	Buy ➝ Buy
TTAN ServiceTitan	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Josh Baer Subscribe to MarketBeat All Access for the recommendation accuracy rating	$93.00 +12.9%	$104.00 ➝ $107.00	Equal Weight ➝ Equal Weight
TTAN ServiceTitan	Reiterated by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Bracelin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$93.00 +12.9%	$125.00 ➝ $125.00	Overweight ➝ Overweight
TTAN ServiceTitan	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Parker Lane Subscribe to MarketBeat All Access for the recommendation accuracy rating	$93.00 +12.9%	$120.00 ➝ $110.00	Buy ➝ Buy
TTAN ServiceTitan	Target Lowered by	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Kim Subscribe to MarketBeat All Access for the recommendation accuracy rating	$93.00 +12.9%	$105.00 ➝ $90.00	Hold ➝ Hold
ULTA Ulta Beauty	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ike Boruchow Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$360.00 ➝ $310.00	Underweight ➝ Underweight
ULTA Ulta Beauty	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lorraine Hutchinson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$475.00 ➝ $380.00	Neutral ➝ Neutral
ULTA Ulta Beauty	Target Lowered by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Korinne Wolfmeyer Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$425.00 ➝ $364.00	Neutral ➝ Neutral
ULTA Ulta Beauty	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Simeon Gutman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$500.00 ➝ $460.00	Overweight ➝ Overweight
ULTA Ulta Beauty	Target Lowered by	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Glaessgen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$430.00 ➝ $330.00	Neutral ➝ Neutral
ULTA Ulta Beauty	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mark Astrachan Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$475.00 ➝ $400.00	Hold ➝ Hold
ULTA Ulta Beauty	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Horvers Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$480.00 ➝ $475.00	Overweight ➝ Overweight
ULTA Ulta Beauty	Target Lowered by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Susan Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$538.00 ➝ $526.00	Buy ➝ Buy
ULTA Ulta Beauty	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Simeon Siegel Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$467.00 ➝ $404.00	Market Perform ➝ Market Perform
ULTA Ulta Beauty	Target Lowered by	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Baker Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$510.00 ➝ $415.00	Buy ➝ Buy
ULTA Ulta Beauty	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Adrienne Yih Subscribe to MarketBeat All Access for the recommendation accuracy rating	$357.48 +13.7%	$445.00 ➝ $327.00	Equal Weight ➝ Equal Weight
VANQ Vanquis Banking Group	Reiterated by	Shore Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		GBX 52.95 -3.6%		House Stock
VIGL Vigil Neuroscience	Target Lowered by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.02 -4.3%	$24.00 ➝ $13.00	Outperform ➝ Outperform
VIGL Vigil Neuroscience	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.02 -4.3%	$17.00 ➝ $14.00	Buy ➝ Buy
VIK Viking	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Scholes Subscribe to MarketBeat All Access for the recommendation accuracy rating	$40.33 +2.9%	$49.00 ➝ $50.00	Hold ➝ Hold
VITL Vital Farms	Target Lowered by	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Holland Subscribe to MarketBeat All Access for the recommendation accuracy rating	$30.94 +5.5%	$44.00 ➝ $42.00	Buy ➝ Buy
VNET VNET Group	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Louis Tsang Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.65 +12.0%	$16.10 ➝ $20.00	Buy ➝ Buy
VNO Vornado Realty Trust	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ronald Kamdem Subscribe to MarketBeat All Access for the recommendation accuracy rating	$36.71 +3.7%	$26.00 ➝ $28.00	Equal Weight ➝ Equal Weight
VNO Vornado Realty Trust	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ross Smotrich Subscribe to MarketBeat All Access for the recommendation accuracy rating	$36.71 +3.7%	$31.00 ➝ $32.00	Underweight ➝ Underweight
VNOM Viper Energy	Initiated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Hanwen Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	$43.30 +4.4%	$51.00	Overweight
WASH Washington Trust Bancorp	Upgraded by	Seaport Res Ptn Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Hunsicker Subscribe to MarketBeat All Access for the recommendation accuracy rating	$30.85 +4.8%		Hold ➝ Strong-Buy
WAY Waystar	Initiated by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$36.47 +3.4%	$45.00	Buy
WEST Westrock Coffee	Reiterated by	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Todd Brooks Subscribe to MarketBeat All Access for the recommendation accuracy rating	$6.88 +24.9%	$10.00 ➝ $10.00	Buy ➝ Buy
WPM Wheaton Precious Metals	Target Raised by	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$106.04 +1.0%	C$78.00 ➝ C$83.00	Buy
WPM Wheaton Precious Metals	Target Raised by	CIBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$106.04 +1.0%	C$85.00 ➝ C$88.00	Outperform
XPOF Xponential Fitness	Downgraded by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris O'Cull Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.45 -38.5%	$20.00 ➝ $12.00	Buy ➝ Hold
XPOF Xponential Fitness	Target Lowered by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Korinne Wolfmeyer Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.45 -38.5%	$16.00 ➝ $9.00	Neutral ➝ Neutral
XPOF Xponential Fitness	Target Lowered by	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jeff Van Sinderen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.45 -38.5%	$12.00 ➝ $9.00	Neutral ➝ Neutral
XPOF Xponential Fitness	Target Lowered by	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Meyers Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.45 -38.5%	$20.00 ➝ $16.00	Buy ➝ Buy
XYZ Block	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	$57.18 +5.8%	$108.00 ➝ $90.00	Buy ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:42 AM ET.

Stock Ratings and Recommendations: Understanding Analyst Ratings

Written by MarketBeat Staff

July 5, 2023

Key Points

Stock analysts give ratings to companies based on their research and insights.
Analysis comes from the buy side (fund companies, investment managers) or sell side (brokers, banks).
Analysts use different methodologies, so investors should always look into why a particular rating was given.
5 stocks we like better than EXA)

You'll often hear a particular stock called a "buy" or "sell," but who exactly makes these calls? Ratings and recommendations come from stock analysts, who research different securities and work for various institutions, brokerage firms and other financial companies.

Analyst ratings are designed to give additional information to investors beyond just what the company is saying, but are analyst ratings reliable? In this article, we'll discuss how to read analyst ratings, what goes into their decision-making process and how potential conflicts of interest influence analyst stock ratings.

What Are Analyst Ratings?

A stock rating is a simple heuristic given by analysts who review the firm's financial statements, listen to conference calls, chat with company executives and compare the stock to others in the industry or sector. Finally, an analyst uses all this information to produce a simple recommendation and price target.

When a public analyst goes on CNBC or the "Wall Street Journal" to give a "buy" or "sell" rating on a particular stock, they take all their research and pare it down into a simple designation. While there's no true consensus on what constitutes a buy or sell rating, an analyst usually does have "skin in the game" when devising ratings.

Ratings often pair with price targets, which put a hard number on what the analysts believe the company stock should be worth. So, for example, you might see an analyst report something like, "Buy NVIDIA Inc. (NASDAQ: NVDA), price target $350," which means that particular analyst believes investors should buy NVDA shares up to a price of $350 per share.

Analyst ratings infographic: What you need to know

What Does a Stock Analyst Do?

A stock analyst is a market professional with the skills to interpret financial data and the connections within companies to speak on the record with higher-ups. Analysts generally fall into one of two different camps: buy-side or sell-side. These positions will seem similar, but they tend to be employed by various institutions and have different responsibilities in their particular market "territories."

Buy-side analysts: Analysts on the buy side tend to work for funds, such as ETF providers or hedge funds. They don't dig as deeply into company financial data or conference calls as sell-siders. Instead, they focus on general areas or industries where their funds have vested interests. In addition, buy-side analysts often forge relationships with sell-side analysts for individual stock research. A buy-side analyst's primary goal is to find and utilize the most accurate and dependable sell-side analysts.
Sell-side analysts: If buy-side analysts work for funds (i.e., institutions that buy securities), you can probably guess which type of institution employs sell-side analysts. Brokers, banks and other firms that sell securities to investors use sell-side analysts to give reports to the public. While buy-side analysts also give ratings and price targets, the reported "buy" and "sell" ratings in financial media typically come from folks on the sell side.

Buy and sell-side analysts often use different rating systems when making their recommendations. You might even find two sell-side analysts with similar "buy" recommendations with vastly different price targets in the same stock. As a result, you'll need to familiarize yourself with the various methodologies analysts use to utilize their research correctly.

What Ratings Do Analysts Give?

Stock analyst ratings don't follow a strict structure, although most have roughly the same grading system for the securities they review. The labels may differ slightly (i.e., overweight vs. outperform), but the five most common analyst ratings go like this.

Buy

Analysts bullish on a particular security will give it a "buy" rating and set a price target above the current market price. In addition, if the analyst considers the stock one of the best in the industry or sector, you'll sometimes see a "strong buy" rating attached.

Hold

A "hold" rating is typically the lowest rating a sell-side analyst gives a stock. "Hold" means the analyst projects the stock to meet the return of the market averages, making it an unspectacular investment. Stocks rated "hold" may still have a price target above the current price, but it's not likely to surpass the return of a major index like the S&P 500.

Sell

Analysts are usually apprehensive about giving a stock a "sell" rating. For example, suppose a "hold" rating indicates indecision over the stock's future. In this scenario, a "sell" rating is issued when an analyst finds something unappealing, such as questionable accounting tactics or cratering sales growth.

Underperform

Analysts won't always give a firm "buy" or "sell" rating on stock but will instead label it "underperform" or "outperform." "Underperform" means the analyst expects the stock not to keep up with the market. It doesn't necessarily mean the analyst predicts a crash but indicates a lack of confidence in the shares.

Outperform

"Outperform" is the opposite of "underperform," meaning the analyst expects the stock to do better than the market average. It's usually considered a less confident rating than "buy."

Example of an Analyst Rating

You can use MarketBeat Analyst Ratings to find ranges and aggregates from buy- and sell-side analysts across the financial media. For example, here's a stock that analysts usually love: Alphabet Inc. (NASDAQ: GOOG).

Overview of stock analysis on GOOG Using MarketBeat's tools, you can find ratings from prominent analysts from multiple periods. Alphabet is currently labeled a "moderate buy" based on MarketBeat's consensus from 17 analysts. You'll get the consensus price target and the highest and lowest from the analysts surveyed.

Marketbeat's tools detailing analyst ratings

Looking at analyst recommendations over time is another helpful tool. For example, you can view the different levels of coverage over the last few years, which analysts changed their ratings and how the price targets vary from month to month. If an analyst can't get a good read on a particular stock they've been covering, they might choose to withhold their grade, which is one reason why the number of available ratings can change over time.

Overview of analyst ratings on MarketBeat Analysts from both sides of the aisle can be found on MarketBeat, ranging from large firms like JPMorgan Chase and Co. (NYSE: JPM) to smaller investment banks like Roth Capital. Some institutions like UBS Group offer both buy-side and sell-side ratings and analysis. These graphs show that even analysts with similar ratings can have vastly different price targets, so always understand the reasoning behind an analyst's view.

How to Use Analyst Ratings

Here are a few pointers on incorporating analyst ratings into your investment research.

Step 1: Don't rely on a single analyst.

Using an array of analysts (buy- and sell-side) gives inventors the most possible information. Don't just look for analysts with similar opinions as yourself — ensure you understand the pros and cons of each investment you make by incorporating positive and negative views, if possible.

Step 2: Compare analyst ratings across the industry or sector.

It's easy to slap a "buy" rating on a stock and predict a winner, but comparing stocks against others in the sector can offer insight into the rating. For example, if a stock is rated "buy" in the information technology sector, but a dozen others are rated "strong buy" by the same analyst, where is your capital best served?

Step 3: Consider your own goals and risk tolerance.

You might find stocks rated "strong buy" in your research in sectors you wish to avoid. That's fine! There are thousands of securities across dozens of industries in the public markets, and you don't need to purchase every share that comes with a "buy" rating. Instead, stick to your investment plan.

Step 4: Don't stubbornly stick to your original assessments.

Following your investment plan and using analyst ratings as guidelines are practical steps, but things can change over time. Today's "strong buy" stocks could be "strong sell" stocks down the road. Using an aggregate of analysts' ratings can help investors view stocks from a higher level. For example, if the number of "buy" ratings on a stock drops 40% over a few years, you might want to take a closer look at that particular company.

Why Are Analyst Ratings Important?

Checking out analyst ratings isn't a necessary step for investing, but it can be helpful for those looking to dig deep into an asset's prospects. Analyst research often has quotes from company executives, questions from conference calls and in-depth reporting on the company's balance sheet, income statement and other essential documents. Analysis like this is complex for individual investors to do on their own, especially considering how frequently analysts interact with the executives they cover. But access often comes with a downside, which we discuss more below.

How Accurate Are Analyst Ratings?

Both buy and sell-side analysts strive for accuracy because giving consistently wrong commendations can be hazardous for job security. However, investors should be aware that analysts might not always have the best interest of the retail investor at heart when making their recommendations.

For starters, being an analyst requires access to company employees and management. Analysts typically ask questions during conference calls and speak with C-suite executives on the record about their firms' prospects. Executives usually don't want to hear adverse reports about their companies, so analysts are incentivized to paint a rosy picture to retain access. The SEC has been questioning the authenticity of analyst ratings (especially on the sell-side) since 2002 when it asked bluntly, "Why are there so few sell ratings?"

Of course, there are other areas of the securities analysis market to face scrutiny. If you recall, during the 2008 financial crisis, the biggest credit rating agencies were all held to the fire due to claims that conflicts of interest influenced their ratings. The biggest rating agencies in the world were accused of "misrepresenting the risks associated with mortgage-backed securities." Remember, analyst ratings aren't spat out by computer algorithms but by living, breathing people who may have agendas other than providing the most precise and accurate reports on a company's future prospects.

Analyst Ratings Can Guide Investors, but Don't Treat Them as Gospel

Consider each type of investment research or advice in collaboration. Even the most accurate and thoughtful analysts get things wrong, plus ratings are frequently besieged with conflicts of interest. But analyst coverage does offer research that's difficult to get elsewhere, and using an array of analyst reports can give investors a deeper understanding of the securities they buy.

FAQs

Still have questions about analyst ratings? Here are a few answers to some common points of discussion:

What are analyst ratings?

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Should you trust analyst ratings?

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

What does an analyst rating tell you about a stock?

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

A Beginner's Guide to Investing in Cannabis Cover

analyst ratings Headlines

How major US stock indexes fared Friday, 3/14/2025
By The Associated Press | March 14, 2025
View How major US stock indexes fared Friday, 3/14/2025
US stocks storm to their best day since November’s election as S&P 500 jumps 2.1%, but worries remain over tariffs
By The Associated Press | March 14, 2025
View US stocks storm to their best day since November’s election as S&P 500 jumps 2.1%, but worries remain over tariffs
In Michigan, Vance says US manufacturing can rebound despite tariff jitters and falling markets
By The Associated Press | March 14, 2025
View In Michigan, Vance says US manufacturing can rebound despite tariff jitters and falling markets
Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
By Thomas Hughes | March 14, 2025
View Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
Costco Price Plunge Equals Opportunity for Investors
By Thomas Hughes | March 11, 2025
View Costco Price Plunge Equals Opportunity for Investors
Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected
By Thomas Hughes | March 7, 2025
View Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected
Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings

Top Headlines and Offers

View All

NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
By Jeffrey Neal Johnson | March 10, 2025
View Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
The real reason gold is soaring (and likely to continue)
From Golden Portfolio(Ad)
View The real reason gold is soaring (and likely to continue)
NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
By Thomas Hughes | March 11, 2025
View NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
S&P 500 & Nasdaq Hit Critical Support—Will Stocks Hold or Fall?
By Jea Yu | March 10, 2025
View S&P 500 & Nasdaq Hit Critical Support—Will Stocks Hold or Fall?
Joby Aviation: From Prototype to Profitability
By Jeffrey Neal Johnson | March 11, 2025
View Joby Aviation: From Prototype to Profitability
This Crypto Is Set to Explode in January
From Crypto 101 Media(Ad)
View This Crypto Is Set to Explode in January
3 Stocks to Buy While Others Stay on the Sidelines
By Chris Markoch | March 8, 2025
View 3 Stocks to Buy While Others Stay on the Sidelines
5 ETFs Poised to Spring Ahead in the Second Quarter
By Chris Markoch | March 11, 2025
View 5 ETFs Poised to Spring Ahead in the Second Quarter
Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
By Thomas Hughes | March 13, 2025
View Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Institutional Investors Bet $1B on These 4 Stocks—Should You?
By Sarah Horvath | March 9, 2025
View Institutional Investors Bet $1B on These 4 Stocks—Should You?
Intel Stock Surges on New CEO – The Real Story Runs Deeper
By Gabriel Osorio-Mazilli | March 13, 2025
View Intel Stock Surges on New CEO – The Real Story Runs Deeper

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stock Price Targets and Analyst Ratings